For gene therapy to improve lung function in cystic fibrosis (CF) subjects, repeated administration of the gene transfer agent over the lifetime of patients is likely to be necessary. This requirement limits the utility of adenoviral and adeno-associated viral vectors (both previously evaluated in CF gene therapy trials) because of induced adaptive immune responses that render repeated dosing ineffective. For CF gene therapy trials, non-viral vectors are currently the only viable option. We previously showed that the cationic lipid formulation GL67A is the most efficient of several non-viral vectors analysed for airway gene transfer. Here, we assessed the efficacy and safety of administering 12 inhaled doses of GL67A complexed with pGM169, a CpG-free plasmid encoding human CFTR complementary DNA, into mice. We show that repeated administration of pGM169/GL67A to murine lungs is feasible, safe and achieves reproducible, dose-related and persistent gene expression (4140 days after each dose) using an aerosol generated by a clinically relevant nebuliser. This study supports progression into the first non-viral multidose lung trial in CF patients.
INTRODUCTION
Cystic fibrosis (CF) is a lifelong disease and airway epithelial cells, the target for CF gene therapy, have a limited lifespan. 1 Only vectors that are effective after repeated administration are, therefore, of clinical relevance unless pulmonary stem cells are targeted. The vast majority of B25 CF trials carried out, to date, have focused on administering a single dose, the effect of which was then tracked over a period of a few weeks. These studies successfully demonstrated proof-ofconcept that gene transfer to airway epithelial cells is feasible, as assessed by molecular end points such as vector-specific mRNA and correction of the CF transmembrane conductance regulator (CFTR)-specific chloride transport defect. There is broad consensus that amelioration of CF lung disease will require prolonged expression of CFTR for many months. However, only three trials using adenovirus and adeno-associated virus vectors [2] [3] [4] have assessed duration in the lung and were defeated by the now well-described adaptive immune responses to these viral vectors. 5 Repeated administration (three doses) of a non-viral vector 3b-[N-(N',N'-dimethylaminoethane)carbamoyl]cholesterol:dioleoylphosphatidylethanolamine (DC-Chol:DOPE) was undertaken in one study in the nose of CF patients, demonstrating efficacy using molecular end points. 6 Although this study used the nasal epithelium as a surrogate and did not include a clinically relevant efficacy end point (that is, measurements in the lung), it provided encouraging proof-ofprinciple for repeat administration of a non-viral gene transfer agent. This led the UK CF Gene Therapy Consortium to undertake an extensive preclinical programme aimed at selecting the most efficient non-viral vector for a multidose CF trial.
The cationic lipid formulation GL67A was ultimately chosen 7 and combined with the CG dinucleotide-free plasmid pGM169, carrying the human CFTR complementary DNA under the control of the hCEFI promoter, which comprises modified versions of the human cytomegalovirus enhancer and elongation factor 1 promoter. 8 Although GL67A had previously been used in CF patients, 9 ,10 the pGM169 plasmid is novel. A single-dose, first-in-man, doseescalation, safety study, demonstrated prolonged (several weeks) restoration of CFTR chloride channel activity after pGM169/GL67A gene transfer in CF patients and allowed for the selection of a dose suitable for use in a multidose clinical study (unpublished observations). Before progression to a multidose clinical trial, there was a scientific and regulatory need to demonstrate that repeated administration of pGM169/GL67A was feasible, efficient and safe in an animal model.
RESULTS AND DISCUSSION
The AeroEclipse II nebuliser generates stable aerosols respirable by mice To mimic our proposed clinical trial conditions, we assessed the suitability of the AeroEclipse II (Trudell Medical International, London, ON, Canada) breath-actuated nebuliser for inhalation toxicology studies in mice. After appropriate optimisation, this nebuliser reproducibly generated stable aerosols of the plasmid DNA/lipid complex that were respirable by mice (mass median aerodynamic diameter 2.0 mm (geometric s.d.: 1.9 mm), n ¼ 10 independent dosing occasions). In our multidose trial, CF patients will be dosed 12 times at monthly intervals; this spacing is based on expression data generated in mice 8 and our recently completed single-dose trial (unpublished observations). To comply with regulatory requirements (European Medicines Agency CPMP/ICH/286/95) cohorts of mice were, therefore, exposed on 12 occasions (every 2 weeks for 6 months taking into account the shorter lifespan of mice) to ambient air (negative control) or low, medium or high doses of aerosolised pGM169/GL67A corresponding to B0, 1.2, 4.6 and 13.1 mg pGM169 per kg per dose and 0, 6.7, 26 and 74 mg GL67A per kg per dose. This dosing range represents an approximate average of 5-, 20-and 60-fold relative to the anticipated human dose (based on a 60-kg patient) for the low-, mediumand high-dose cohorts, respectively. The most appropriate treatment for the negative control group was extensively discussed. The solvent for GL67A and pGM169 is water. However, it is generally accepted that repeated administration of hypotonic solutions lead to bronchoconstriction and other Figure 1 . Plasmid DNA in murine lungs after single and repeated aerosolisation of low, mid and high doses of pGM169/GL67A complexes. Mice (five males þ five females per group) received 1, 6 or 12 deliveries of aerosolised pGM169/GL67A complexes for 0.5 (low), 2 (mid) or 6 h (high dose) or received 1, 6 or 12 deliveries of air only for 6 h. (a) One day after the last treatment, pGM169 DNA was quantified in lungs using quantitative (Q)-PCR. All air-only animals (n ¼ 30) are pooled for convenience. (b) Mice in the high-dose cohort (6 h treatment) were culled 1, 56 or 147 days after 1 or 12 deliveries. All air-only animals (n ¼ 42) are pooled for convenience. Low levels of pGM169 were detectable in a small number of air-control animals because of sample contamination during harvesting, processing or analysis, a common problem associated with Q-PCR-based DNA detection methods. This finding did not affect interpretation of the results. Data are expressed as copies of pGM169 per mg total DNA. Each symbol represents one animal and the group median is shown as a horizontal bar. PBNQ ¼ positive, but not quantifiable because lower than the standard curve. ***Po0.001 compared with day 1, þ þ Po0.01 compared with one delivery at day 147 and þ þ þ Po0.001 compared with one delivery at day 56. side effects and, would, therefore, not constitute an appropriate control for the GL67A/pGM169 formulation. We considered administration of 'lipid-only', but the properties (including particle size and charge) are very different compared with a lipid/DNA formulation and unlikely, therefore, to be a suitable control. Saline is being used as the placebo in our on-going multidose trial, but experts had concerns related to repeated and prolonged administration to mice because of the smaller diameter of the airways. On balance 'snout-only' exposure to ambient air was therefore considered the most appropriate negative control to assess the effects of lipid/DNA administration in mice.
Plasmid deposition is dose related and reproducible upon repeated delivery In addition to a full range of toxicological investigations, molecular analysis using quantitative PCR and quantitative reverse transcriptase PCR was performed in the lung (the target organ) and in seven non-target organs.
Deposition of plasmid DNA in the lung was dose related (Spearman's correlation: r40.85 and Po0.0001, n ¼ 5 per sex per group) when comparing low-, mid-and high-dosing cohorts after 1, 6 and 12 deliveries, with consistent levels of plasmid deposition achieved with each delivery of pGM169/GL67A (Figure 1a) , Figure 2 . pGM169 mRNA in murine lungs after single and repeated aerosolisation of low, mid and high doses of pGM169/GL67A complexes. Mice (five males þ five females per group) received 1 or 12 deliveries of aerosolised pGM169/GL67A complexes for 0.5 (low), 2 (mid) or 6 h (high dose) or received 1, 6 or 12 deliveries of air only for 6 h. (a) One day after the last treatment, vector-specific pGM169 mRNA was quantified in lungs using quantitative reverse transcriptase PCR. All air-only animals (n ¼ 30) are pooled for convenience. Data are expressed as copies of vector-specific pGM169 mRNA per mg total RNA. **Po0.01, ***Po0.001 compared with air-only controls. (b) Mice aerosolised for 6 h (high-dose cohort) were culled 1, 56 or 147 days after 1 or 12 deliveries. All air-only animals (n ¼ 42) are pooled for convenience. Data are expressed as copies vector-specific pGM169 mRNA per mg total RNA. *Po0.05 compared with day 1, ***Po0.001 compared with air-only controls. pGM169 mRNA was detectable in a small number of air-control animals because of sample contamination during harvesting, processing or analysis, a common problem associated with PCR-based mRNA detection methods. This finding did not affect interpretation of the results. Each symbol represents one animal and the group median is shown as a horizontal bar. PBNQ ¼ positive, but not quantifiable because lower than the standard curve.
thereby confirming the reproducible delivery of pGM169/GL67A with the AeroEclipse II nebuliser.
Plasmid DNA persists over time Plasmid DNA was detectable for more than 4 months after delivery. Consistent with previously reported degradation profiles, 11 the amount of pGM169 was approximately three logs lower (Po0.001, n ¼ 10 per group) at 56 days compared with 1 day after 1 and 12 deliveries (Figure 1b) . Thereafter (day 147), the rate of degradation slowed (n ¼ 5 per sex per dose per time point). The levels of plasmid DNA after 12 deliveries were approximately 6-fold higher (Po0.0001, n ¼ 10 per group) at day 56 and 1.6-fold higher (Po0.01, n ¼ 10 per group) at day 147 when compared with a single delivery. A limitation of quantitative PCR is that the assay does not discriminate between intact and partially degraded plasmids, or between intra-and extracellular DNA. We speculate that the rapid loss of pGM169 at earlier time points after administration is predominantly due to degradation of extracellular and cytoplasmic DNA, whereas the comparatively low but more stable levels at later time points may reflect plasmid DNA that has entered the nucleus and is contributing to recombinant protein expression. mRNA expression is dose related Similar to pGM169 DNA deposition, there was a significant correlation between the amount of pGM169/GL67A delivered (low, medium and high dose) and the amount of vector-specific mRNA (copies per mg total RNA) detected 24 h after 1 delivery (r ¼ 0.76, Po0.0001, n ¼ 10 per group; Figure 2a ). Although these data support a simplistic 'more is better' interpretation, as part of our single-dose pilot study we determined a comparatively narrow efficacy-toxicity window, which may limit the amount of pGM169/GL67A that could be administered per dose to CF patients. In contrast, to pGM169 DNA deposition, we did not detect a significant correlation between the amount of pGM169/ GL67A delivered (low, medium and high dose) and the amount of vector-specific mRNA (copies per mg total RNA) detected 24 h after 12 deliveries (Figure 2a ). This may relate to the mild, dose-related inflammatory responses described below preventing augmentation of expression in the mid-and high-dose groups. The PCRbased method used here to quantify gene expression does not provide information about the number or type of cell transfected. However, CFTR immunohistochemistry-based assays, required to address this, are not sufficiently sensitive to detect gene expression after non-viral gene transfer to airway epithelial cells in vivo, although high levels of mRNA are detectable.
CFTR expression persists for more than 4 months We have previously shown that the hCEFI promoter supports gene expression for at least 2 months after dosing. 8 Here, we assessed the duration of pGM169-mediated CFTR mRNA expression in the high-dose cohort after 1 and 12 deliveries and found no differences. In contrast to the plasmid DNA profile, CFTR mRNA levels dropped by B1 log when comparing day 1 and day 56 expression levels after 1 (not significant, n ¼ 10 per group) and 12 deliveries (Po0.05, n ¼ 10 per group), and thereafter remained stable and significantly (Po0.001) higher than controls for at least 4.5 months (Figure 2b ).
Plasmid DNA and vector-specific CFTR mRNA in non-target organs To mimic a 'worst-case' scenario, the biodistribution of pGM169 plasmid DNA in non-target organs was assessed in the high-dose cohort and compared with the air control cohort. As expected, low levels of pGM169 DNA were detectable in all organs tested (testes, Figure 3 . pGM169 DNA in murine spleens after single and repeated aerosolisation of low, mid and high doses of pGM169/GL67A complexes. Mice (five males þ five females per group) received 1 or 12 deliveries of aerosolised pGM169/GL67A complexes for 0.5 (low), 2 (mid) or 6 h (high dose) or received 1 or 12 deliveries of air only for 6 h. One day after the last treatment, pGM169 DNA was quantified in the spleen using quantitative PCR. All air-only animals (n ¼ 12) are pooled for convenience. Data are expressed as copies of pGM169 DNA per mg total DNA. Each symbol represents one animal and the group median is shown as a horizontal bar. PBNQ ¼ positive, but not quantifiable because lower than the standard curve. ABAC ¼ levels at or below air-only control levels. Dotted line ¼ levels of pGM169 DNA detected in lungs (shown as reference).
ovaries, spleen, gut, liver, kidney, cervical lymph nodes and blood) 1 day after delivery 1 and 12. These levels were between five and eight orders of magnitude lower than detected in the lung, with no evidence for DNA accumulation after multiple doses (data not shown). By day 56 after delivery, pGM169 DNA levels had declined to background levels in all non-target organs except the spleen where a low level of pGM169 DNA (approximately five orders of magnitude less than that in the lungs) remained detectable 147 days after dose 12 ( Figure 3 ). This may be related to DNA uptake by macrophages that have a lifespan of several months. 12 It is unlikely that the very low levels of plasmid DNA (which is most probably partially degraded) would lead to safety concerns. This is supported by the fact that no vector-specific mRNA was detected in any non-target organ 1 day after dose 12, when the highest expression levels would have been expected.
No evidence of cumulative toxicity was seen Repeat administration of 12 deliveries of pGM169/GL67A did not lead to treatment-related effects on clinical signs and ophthalmoscopy findings. Body weight gain and food consumption in all dosing cohorts (including air controls) fluctuated but they were not treatment related and were probably because of distress caused during the prolonged (B6.5 h) restraining period in the exposure tubes (Figure 4) . Two days after delivery 12, we detected marginal increases in serum haptoglobin (males and females), blood neutrophils and white blood cells (males only) and lung weight (males and females) in the high-dose cohort (B60-fold over human dose), which had returned to baseline 2 weeks after dosing (Table 1) . This is consistent with mild acute systemic inflammation. Two weeks after delivery 12, a time point selected to avoid masking of chronic histological changes by the acute and transient neutrophilic infiltration that we had previously observed 1-2 days after treatment, 7 some test item-related histopathological Because of low n numbers, males and females were analysed together.
changes were detectable in lungs of all dose cohorts ranging from a few scattered macrophages (low-dose cohort) to foamy macrophage accumulation and mild inflammation (high-dose cohort) ( Figure 5 ). Following a 13-week recovery period, these changes were no longer detectable in the low-(fivefold over human) dose cohort, but some changes persisted in the mid-and high-(20-and 60-fold over human) dose cohorts. We also observed dose-related changes in the nasal cavity of the high-, but not the low-and mid-dose cohorts. Some olfactory epithelial atrophy and an increased incidence of eosinophils in the respiratory epithelium were observed. During the 13-week recovery period, the olfactory epithelial atrophy was only partly reversed (data not shown). Degeneration of the olfactory epithelium in the nasal cavity of mice is a common response to an inhaled irritant and these changes were not considered to be of clinical concern, as obligate nose breathers, mice will have inhaled the plasmid DNA/lipid complexes through the nasal passages. In contrast, trial participants will use mouth pieces and nose clips, and significant exposure of the olfactory epithelium to the complexes will not be anticipated. Importantly, there were no histopathological changes in any of the more than 40 non-target organs analysed nor did the other investigations indicate a general toxic action.
On the basis of data described above, the no-adverse-effectlevel for pGM169/GL67A was considered to be the low dose corresponding to 1.2 mg pGM169 per kg per dose and 6.7 mg GL67A per kg per dose based on minimal histological changes in the lungs following 12 deliveries and no persisting changes after 13 weeks.
In conclusion, we show that (1) reproducible and dose-related delivery of pGM169/GL67A complexes to murine lungs is feasible using a clinically relevant nebuliser, (2) gene expression is doserelated and persists for at least 3 months and (3) importantly, repeated gene transfer (12 doses) is safe. This study, therefore, lends strong support for progression to a double-blinded placebocontrolled phase IIb clinical trial in CF patients, which is now underway and scheduled to be completed in summer 2014. If replicated in man, the high and reproducible levels of vectorspecific gene expression that can be achieved following repeated application of the non-viral gene transfer complexes open the door for wider applications. Specifically, using the lung as a factory to produce secreted proteins acting either locally (for example, a1 anti-trypsin) or systemically (for example, factor VIII/IX) may now be achievable using this strategy.
MATERIALS AND METHODS
BALB/c mice (Charles River UK Ltd, Margate, UK), rather than the CD1 mice that are commonly used for toxicity studies, were used for this study because we have previously shown that GL67A-mediated lung gene transfer is approximately one log order higher in BALB/c mice compared with CD1 mice (unpublished observations). Males (n ¼ 332) and females (n ¼ 332) were allocated to four dose groups (air control, low, mid and high doses). On commencement of dosing, the animals were 8-9 weeks old with mean weights of 21.7 and 18.1 g for males and females, respectively. Mice were exposed to air (controls) or the aerosol by a snout-only technique. The negative control animals were exposed to air rather than water, saline or lipid because none of these solutions accurately control for the effect of GL67A/pGM169 administration. Importantly, lipid-only may stimulate different in vivo responses compared with lipid/DNA administration and, was, therefore, thought not to be an appropriate control. Clinical grade pGM169 and GL67A were manufactured by VGXi (Houston, TX, USA) and OctoPlus (Leiden, Holland), respectively, and were complexed as previously described 9, 13 to achieve a concentration of B150 mg GL67A and 26.5 mg pGM169 per 10 ml complex. Complexes were aerosolised using an AeroEclipse II nebuliser (Trudell Medical International), with two nebulisers (required to achieve the necessary aerosol concentration) attached to each administration chamber to which snout-only exposure outlets were connected (see Supplementary Figure 1 ). The overall airflow to the chamber was B18 l min À 1 ; 6 l min À 1 to each nebuliser and 6 l min À 1 dilution air. The dilution air was included to promote the generation of a 'dry' aerosol and thereby maintain the droplet size distribution within the target range (the respirable droplet size for mice is 1-4 mm). To help achieve this objective, the dilution air was warmed before entering the chamber by submerging the air tube in a water bath heated to 60 1C. Using these conditions, it took B20 min to aerosolise 10 ml pGM169/GL67A. For analytical purposes, aerosol samples were collected from a standard reference port in the exposure chamber using a glass fibre filter (Whatman GF/B 47 mm) placed in a filter held in-line with the sampling system. Filters were weighed before and after sampling and the aerosol concentration (total formulation calculated from the difference Figure 5 . Histopathological findings in lungs of mice exposed 12 times to aerosolised pGM169/GL67A at 2-week intervals. Animals were culled 2 weeks after the last delivery. between pre-and post-sample filter weights and divided by the total sampling volume) was determined. Chemical analysis of samples collected on gravimetric filters was subsequently undertaken. Filters were placed into amber jars containing lipid extraction solvent (60:20:10:10:0.5 (v/v/v/v/v) methanol: 2-propanol: Milli-Q H 2 O:chloroform: formic acid) and analysed using high performance liquid chromatography. The mean aerosol concentration for deliveries 1-12 was 0.14 ± 0.021 mg GL67A/L. The aerodynamic particle size distribution of pGM169/GL67A aerosols was assessed using cascade impactors (Dekati or Marple 296) and chemical analysis.
Animals were dosed by snout-only exposure in cone-shaped restraining tubes once every 2 weeks for 23 weeks (12 separate doses). Different dose levels were achieved by varying the exposure time: low-dose animals were dosed with pGM169/GL67A for 0.5 h plus 5.5 h of ambient air, mid-dose animals were dosed for 2 h plus 4 h of ambient air and high-dose animals were dosed for 6 h. Air control animals were exposed to ambient air for 6 h. Dose levels were estimated based on the analytically determined concentration of GL67A because the lipid to plasmid ratio is constant during nebulisation. 14 The following formula was used: dose (mg kg 
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